{"id":1779,"date":"2023-02-28T16:35:36","date_gmt":"2023-02-28T16:35:36","guid":{"rendered":"http:\/\/proboostnow.eu\/?page_id=1779"},"modified":"2024-07-18T16:21:10","modified_gmt":"2024-07-18T16:21:10","slug":"tpa-v-terapii-felv-vedecke-studie","status":"publish","type":"page","link":"https:\/\/proboostnow.eu\/en_us\/tpa-v-terapii-felv-vedecke-studie\/","title":{"rendered":"TPA V TERAPII FeLV V\u011aDECK\u00c9 STUDIE"},"content":{"rendered":"<div class=\"banner has-hover\" id=\"banner-1122341442\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" >\n            <img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"593\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/cat-g81ba0f6b8_1920-1024x595.jpg\" class=\"bg attachment-large size-large\" alt=\"TPA V TERAPII FeLV V\u011aDECK\u00c9 STUDIE\" \/>                                    \n                    <\/div>\n\t\t\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n\n   <div id=\"text-box-152659909\" class=\"text-box banner-layer x50 md-x50 lg-x50 y50 md-y50 lg-y50 res-text\">\n                                <div class=\"text-box-content text dark\">\n              \n              <div class=\"text-inner text-center\">\n                  \n\n<h2 class=\"entry-title\">ProBoost v terapii FeLV, v\u011bdeck\u00e9 studie\u00a0<\/h2>\n\n              <\/div>\n           <\/div>\n                            \n<style>\n#text-box-152659909 {\n  width: 94%;\n}\n#text-box-152659909 .text-box-content {\n  font-size: 100%;\n}\n<\/style>\n    <\/div>\n \n\n        <\/div>\n      <\/div>\n\n            \n<style>\n#banner-1122341442 {\n  padding-top: 500px;\n}\n<\/style>\n  <\/div>\n\n\n\t<div id=\"gap-1349647958\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1349647958 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div id=\"gap-92128448\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-92128448 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n<div class=\"row\"  id=\"row-1725108695\">\n\n\n\t<div id=\"col-1049964060\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-1022370021\" class=\"text\">\n\t\t\n\n<p>ProBoost\u00aeThymic Protein A navazuje jako peror\u00e1ln\u00ed podoba se stejnou \u00fa\u010dinnou l\u00e1tkou na injek\u010dn\u00ed l\u00e9k T-cyte (<a href=\"http:\/\/tcyte.com\/\">http:\/\/tcyte.com\/<\/a>), kter\u00fd byl uzn\u00e1n americkou USDA v roce 2008 jako l\u00e9k na osteoartritidu ps\u016f a na l\u00e9\u010dbu FIV a FeLV u ko\u010dek. Stejn\u00fd glykoprotein m\u00e1 u injek\u010dn\u00edho p\u0159\u00edpravku obchodn\u00ed n\u00e1zev LCTI u peror\u00e1ln\u00edho TPA<\/p>\n<p>Za v\u00edce ne\u017e dek\u00e1du, kdy byl p\u0159ed expirac\u00ed licence LTCI pro terapii FeLV a FIV nemocn\u00fdch ko\u010dek vyu\u017e\u00edv\u00e1n, zachr\u00e1nil \u017eivot a p\u0159edev\u0161\u00edm jeho kvalitu tis\u00edc\u016fm zv\u00ed\u0159at. Na\u0161t\u011bst\u00ed ProBoost se stal plnohodnotnou a levn\u011bj\u0161\u00ed n\u00e1hradou a tak m\u016f\u017ee thymov\u00fd protein pom\u00e1hat d\u00e1l. V kapitole <strong>Pou\u017eit\u00ed LTCI \/ TPA, praktick\u00e9 zku\u0161enosti majitel\u016f a odborn\u00edk\u016f<\/strong>\u00a0najdete recenze a zku\u0161enosti konkr\u00e9tn\u00edch u\u017eivatel\u016f.\u00a0<\/p>\n<p class=\"has-tertiary-background-color has-background\">\u00a0<\/p>\n\t\t\n<style>\n#text-1022370021 {\n  color: rgb(0,0,0);\n}\n#text-1022370021 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-1458252184\">\n\n\n\t<div id=\"col-2041725040\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\n<a href=\"\/en_us\/felv-proboost-prakticke-zkusenosti\/\" class=\"button primary is-outline box-shadow-5 box-shadow-5-hover\"  style=\"border-radius:10px;\">\n\t\t<span>Pou\u017eit\u00ed LTCI \/ TPA v praxi<\/span>\n\t<\/a>\n\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\t<div id=\"gap-467874185\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-467874185 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div id=\"text-466300600\" class=\"text\">\n\t\t\n\n<h3 style=\"text-align: center;\">Vliv\u00a0 brzl\u00edkov\u00e9ho proteinu A na\u00a0 ko\u010dky s diagn\u00f3zou FeLV a FIV<\/h3>\n<h5>ProBoost nen\u00ed l\u00e9k na FeLV a FIV, m\u016f\u017ee ale jako p\u0159irozen\u00fd siln\u00fd imunomodul\u00e1tor hr\u00e1t z\u00e1sadn\u00ed \u00falohu p\u0159i vyl\u00e9\u010den\u00ed nebo p\u0159echodu do bezp\u0159\u00edznakov\u00e9 remise. U t\u011b\u017ek\u00fdch a komplikovan\u00fdch infekc\u00ed alespo\u0148 v\u00fdznamn\u011b p\u0159isp\u00edv\u00e1 ke zlep\u0161en\u00ed komfortu \u017eivota zlep\u0161en\u00edm obranyschopnosti imunodeficientn\u00edho pacienta.\u00a0\u00a0<\/h5>\n\t\t\n<style>\n#text-466300600 {\n  color: rgb(0,0,0);\n}\n#text-466300600 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-454786730\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-454786730 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n<div class=\"row\"  id=\"row-1299958052\">\n\n\n\t<div id=\"col-1656590275\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-1879281428\" class=\"text\">\n\t\t\n\n<p>Na po\u010d\u00e1tku byla studie, jej\u00edm\u017e c\u00edlem bylo na imunodeficientn\u00edm zv\u00ed\u0159ec\u00edm modelu, tedy FIV a FeLV pozitivn\u00edch ko\u010dk\u00e1ch, zjistit efekt pod\u00e1v\u00e1n\u00ed TPA na zlep\u0161en\u00ed stavu jejich imunitn\u00edho syst\u00e9mu.<\/p>\n<p>Tento model byl zvolen pro z\u00e1kladn\u00ed v\u00fdzkum lidsk\u00e9ho onemocn\u011bn\u00ed AIDS a ji\u017e d\u0159\u00edve byla provedena studie virov\u00e9 imunodeficience u experiment\u00e1ln\u011b naka\u017een\u00fdch ko\u010dek. V\u011bdci sledovali terapeutick\u00fd \u00fa\u010dinek TPA na zv\u00ed\u0159atech, kter\u00e1 byla pou\u017eita jako infikovan\u00e1 kontrola p\u0159i v\u00fdvoji vakc\u00edny na pracovi\u0161ti Dr. Pedersena v UC Davis. Pozitivn\u00ed zji\u0161t\u011bn\u00ed vedla k dal\u0161\u00edm klinick\u00fdm experiment\u016fm zam\u011b\u0159en\u00fdm na l\u00e9\u010dbu FIV a FeLV u ko\u010dek.<\/p>\n<p class=\"has-base-background-color has-background\">Zjednodu\u0161en\u00fd stru\u010dn\u00fd obsah jedn\u00e9 z klinick\u00fdch studi\u00ed:<\/p>\n<p class=\"has-tertiary-background-color has-background\">Za \u00fa\u010delem zji\u0161t\u011bn\u00ed, zda m\u016f\u017ee b\u00fdt TPA pou\u017eit jako imunoterapeutick\u00fd prost\u0159edek u imunitn\u011b oslaben\u00fdch jedinc\u016f nap\u0159\u00edklad HIV pozitivn\u00edch byl zvolen preklinick\u00fd model FIV a FeLV infikovan\u00fdch ko\u010dek. Virus infikuje CD4+ helper T lymfocyty, co\u017e zp\u016fsob\u00ed pokles po\u010dtu b\u00edl\u00fdch krvinek (WBC). To m\u00e1 za n\u00e1sledek zv\u00fd\u0161enou vn\u00edmavost pro oportunn\u00ed infekce u naka\u017een\u00fdch zv\u00ed\u0159at. V pilotn\u00ed klinick\u00e9 studii <strong>bylo shrom\u00e1\u017ed\u011bno 23 p\u0159irozen\u011b infikovan\u00fdch ko\u010dek<\/strong>. Podm\u00ednkou pro za\u0159azen\u00ed do studie byla jedin\u00e1 infekce (bu\u010f FIV nebo FeLV) a alespo\u0148 dva jej\u00ed symptomy. Byly odebr\u00e1ny vzorky krve p\u0159ed zah\u00e1jen\u00edm terapie. Potom byla pod\u00e1na\u00a0<strong>prvn\u00ed d\u00e1vka 1 pg podko\u017en\u011b, dal\u0161\u00ed byla aplikov\u00e1na 14. a 28. den<\/strong>. P\u0159ed posledn\u00ed injekc\u00ed byl odebr\u00e1n op\u011bt vzorek krve. Byla srovn\u00e1na hladina lymfocyt\u016f se stavem p\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby.<\/p>\n<p class=\"has-tertiary-background-color has-background\"><strong>Ko\u010dky,\u00a0<\/strong><strong>kter\u00e9\u00a0<\/strong><strong>byly p\u0159ijaty do<\/strong><strong>\u00a0studie byly chronicky a v\u00e1\u017en\u011b nemocn\u00e9\u00a0<\/strong>v dob\u011b, kdy byly majiteli p\u0159ineseny na kliniku.\u00a0<strong>N\u011bkter\u00e9 z nich byly ve stavu, kdy byla veterin\u00e1\u0159em nebo majitelem doporu\u010dov\u00e1na euthanasie<\/strong>. Diagn\u00f3za FIV, resp. FeLV byla jednozna\u010dn\u011b potvrzena laboratorn\u00ed anal\u00fdzou. V\u011bt\u0161ina ko\u010dek trp\u011bla lymfopeni\u00ed bu\u010f v r\u00e1mci diferenci\u00e1ln\u00edho rozpo\u010dtu nebo v absolutn\u00edch hodnot\u00e1ch celkov\u00e9ho po\u010dtu. V\u011bt\u0161inou se tak\u00e9 vyskytla anemie, n\u011bkdy velmi z\u00e1va\u017en\u00e1 (hematokrit 8 a\u017e 12 %). U dvou ko\u010dek byla tak\u00e9 granulocytopenie.\u00a0<strong>Zlep\u0161en\u00ed klinick\u00e9ho stavu bylo majiteli pozorov\u00e1no ji\u017e b\u011bhem 72 hodin po prvn\u00ed injekci<\/strong>. Mno\u017estv\u00ed lymfocyt\u016f se po l\u00e9\u010db\u011b zvedlo pr\u016fm\u011brn\u011b o 38 %.<\/p>\n<p class=\"has-tertiary-background-color has-background\">Protein pou\u017eit\u00fd ve studii byl nazv\u00e1n Lymfocyte T Cell Immunomodulator (LTCI), v pr\u00e1\u0161kov\u00e9 per or\u00e1ln\u00ed podob\u011b m\u00e1 licencovan\u00fd n\u00e1zev Thymic Protein A (TPA).<\/p>\n<p class=\"has-tertiary-background-color has-background\"><strong>Prokazateln\u011b se zlep\u0161il imunitn\u00ed stav nemocn\u00fdch zv\u00ed\u0159at, signifikantn\u011b se zlep\u0161ily klinick\u00e9 symptomy a p\u011bt let po ukon\u010den\u00ed studie tento stav p\u0159etrv\u00e1val. Nebyly pozorov\u00e1ny \u017e\u00e1dn\u00e9 v\u00e1\u017en\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky.\u00a0<\/strong><\/p>\n\t\t\n<style>\n#text-1879281428 {\n  color: rgb(0,0,0);\n}\n#text-1879281428 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-1967938394\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1967938394 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div id=\"gap-1973190644\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1973190644 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n  <div class=\"banner has-hover bg-zoom-fade\" id=\"banner-1776341578\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" >\n            <img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"675\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/adorable-g31b2c8dca_1280-1024x678.jpg\" class=\"bg attachment-large size-large\" alt=\"FeLV a terapi ProBoostem\" \/>                        <div class=\"overlay\"><\/div>            \n                    <\/div>\n\t\t\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n\n   <div id=\"text-box-1072390492\" class=\"text-box banner-layer x5 md-x0 lg-x0 y50 md-y95 lg-y95 res-text\">\n                                <div class=\"text-box-content text dark\">\n              \n              <div class=\"text-inner text-center\">\n                  \n\n\t<div id=\"text-181497854\" class=\"text\">\n\t\t\n\n<h4>ProBoost nen\u00ed l\u00e9k na FeLV a FIV, m\u016f\u017ee ale hr\u00e1t z\u00e1sadn\u00ed \u00falohu p\u0159i vyl\u00e9\u010den\u00ed nebo p\u0159echodu do bezp\u0159\u00edznakov\u00e9 remise. U t\u011b\u017ek\u00fdch infekc\u00ed alespo\u0148 v\u00fdznamn\u011b p\u0159isp\u00edv\u00e1 ke zlep\u0161en\u00ed komfortu \u017eivota zlep\u0161en\u00edm obranyschopnosti imunodeficientn\u00edho pacienta.\u00a0\u00a0<\/h4>\n<h5><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">K tvrzen\u00ed, \u017ee TPA je l\u00e9k na FeLV a FIV p\u0159istupujeme se v\u0161\u00ed pokorou a obez\u0159etnost\u00ed. Za spr\u00e1vn\u011bj\u0161\u00ed pova\u017eujeme jeho klasifikaci jako velmi siln\u00fd a \u00fa\u010dinn\u00fd p\u0159irozen\u00fd imunomodul\u00e1tor, kter\u00fd\u00a0 funkc\u00ed i chemick\u00fdm slo\u017een\u00edm p\u0159\u00edslu\u0161\u00ed k cytokin\u016fm nebo interferon\u016fm a je nezbytnou sou\u010d\u00e1st\u00ed imunitn\u00edho syst\u00e9mu v\u0161ech savc\u016f. Nen\u00ed to farmakologicky \u00fa\u010dinn\u00fd l\u00e9k, jak\u00fdm jsou nap\u0159\u00edklad um\u011bl\u00e1 antivirotika nebo antibiotika. TPA v organismu ko\u010dky aktivuje p\u0159irozen\u00e9 biologick\u00e9 obrann\u00e9 procesy, i ty, kter\u00e9 u n\u00ed nemoc potla\u010dila nebo vy\u0159adila a to velmi specificky. Je nutn\u00e9 si uv\u011bdomit, \u017ee v\u017edy z\u00e1le\u017e\u00ed na konkr\u00e9tn\u00edm jedinci, na konkr\u00e9tn\u00edm pr\u016fb\u011bhu nemoci a m\u00ed\u0159e po\u0161kozen\u00ed jeho imunity. ProBoost nem\u016f\u017ee pomoci v\u0161em nemocn\u00fdm ko\u010dk\u00e1m se zcela uzdravit, zejm\u00e9na vzhledem k tomu, \u017ee v dob\u011b jeho nasazen\u00ed se ji\u017e n\u011bkter\u00e9 z nich mohou pot\u00fdkat z \u0159adou nezvratn\u00fdch po\u0161kozen\u00ed organismu a oportunn\u00edch infekc\u00ed, tak\u017ee stoj\u00edme proti cel\u00e9mu spektru protivn\u00edk\u016f. ProBoost<\/span><\/span><\/span><strong><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>\u00ae<\/b><\/span><\/span><\/span><\/strong><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Thymic Protein A nen\u00ed univerz\u00e1ln\u00ed \u017eiv\u00e1 voda a neum\u00ed rovnat zlomeniny, co ale opravdu um\u00ed dokonale, je nastartovat imunitn\u00ed syst\u00e9m t\u00edm, \u017ee z\u00e1sadn\u00edm zp\u016fsobem zasahuje do jeho nejvy\u0161\u0161\u00edch \u0159\u00edd\u00edc\u00edch pater \u2013 ovliv\u0148uje jak\u00e9si \u201e\u0159\u00edd\u00edc\u00ed centrum bun\u011b\u010dn\u00e9 imunity\u201c, kter\u00fdm jsou T lymfocyty \u2013 podle sv\u011btov\u011b uzn\u00e1van\u00e9 \u010desk\u00e9 imunolo\u017eky prof. RNDr. Blanky \u0158\u00edhov\u00e9<\/span><\/span><\/span><strong><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>,<\/b><\/span><\/span><\/span><\/strong><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> DrSc jsou to v pravd\u011b \u201edirigenti imunitn\u00edho syst\u00e9mu\u201c. Jsou to bu\u0148ky, kter\u00e9 um\u00ed \u0159\u00eddit imunitn\u00ed reakci na nejr\u016fzn\u011bj\u0161\u00edch \u00farovn\u00edch t\u00edm, \u017ee vys\u00edlaj\u00ed sign\u00e1ly dal\u0161\u00edm \u201ebojov\u00fdm i v\u00fdrobn\u00edm jednotk\u00e1m imunitn\u00edho syst\u00e9mu\u201c. Kde je t\u0159eba p\u0159idat, tam akceleruj\u00ed, kde je pot\u0159eba reakci tlumit, tam p\u0159ibrzd\u00ed. V tom je ohromn\u00fd uzdravuj\u00edc\u00ed potenci\u00e1l ProBoostu a proto je doporu\u010denou d\u016fle\u017eitou ka\u017edodenn\u00ed sou\u010d\u00e1st\u00ed p\u00e9\u010de o FeLV a FIV pozitivn\u00ed pacienty.<\/span><\/span><\/span><\/h5>\n\t\t\n<style>\n#text-181497854 {\n  color: rgb(144, 24, 2);\n}\n#text-181497854 > * {\n  color: rgb(144, 24, 2);\n}\n<\/style>\n\t<\/div>\n\t\n\n              <\/div>\n           <\/div>\n                            \n<style>\n#text-box-1072390492 {\n  width: 60%;\n}\n#text-box-1072390492 .text-box-content {\n  font-size: 100%;\n}\n@media (min-width:550px) {\n  #text-box-1072390492 {\n    width: 70%;\n  }\n}\n<\/style>\n    <\/div>\n \n\n        <\/div>\n      <\/div>\n\n            \n<style>\n#banner-1776341578 {\n  padding-top: 700px;\n}\n#banner-1776341578 .overlay {\n  background-color: rgba(0, 0, 0, 0);\n}\n#banner-1776341578 .banner-bg img {\n  object-position: 75% 96%;\n}\n<\/style>\n  <\/div>\n\n\n\t<div id=\"gap-1496290474\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1496290474 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\t<div id=\"text-3145159156\" class=\"text\">\n\t\t\n\n<h3 style=\"text-align: center;\">Jak konkr\u00e9tn\u011b ProBoost &#8211; Thymic Protein A\u00a0 pom\u00e1h\u00e1?<\/h3>\n\t\t\n<style>\n#text-3145159156 {\n  color: rgb(0,0,0);\n}\n#text-3145159156 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-359881465\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-359881465 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div id=\"text-1747717639\" class=\"text\">\n\t\t\n\n<p>Ji\u017e 15 let brzl\u00edkov\u00fd protein A (TPA, LCTI) pom\u00e1h\u00e1 ko\u010dk\u00e1m naka\u017een\u00fdm FeLV pos\u00edlen\u00edm jejich adaptivn\u00ed imunitn\u00ed odpov\u011bdi, kterou decimuje virus felinn\u00ed leuk\u00e9mie. D\u00edky zv\u00fd\u0161en\u00ed po\u010dtu a aktivaci sp\u00edc\u00edch naivn\u00edch CD4+ T helper lymfocyt\u016f, kter\u00e9 vyvolaj\u00ed plej\u00e1du nesm\u00edrn\u011b \u00fa\u010dinn\u00fdch, siln\u00fdch, specifick\u00fdch a p\u0159\u00edsn\u011b regulovan\u00fdch imunitn\u00edch proces\u016f, je znovu pos\u00edlena virem oslaben\u00e1 imunita a t\u011blo op\u011bt z\u00edsk\u00e1 schopnost se br\u00e1nit proti nemoci. Pokud nedojde s jeho p\u0159i\u010din\u011bn\u00edm k \u00fapln\u00e9mu uzdraven\u00ed, alespo\u0148 velice v\u00fdznamn\u00fdm zp\u016fsobem pom\u00e1h\u00e1 ko\u010dk\u00e1m prodlou\u017eit \u017eivot a hlavn\u011b udr\u017eet co nejd\u00e9le jeho kvalitu.\u00a0<\/p>\n<h5>Brzl\u00edkov\u00fdm proteinem A aktivovan\u00e1 adaptivn\u00ed specifick\u00e1 imunitn\u00ed reakce se zam\u011b\u0159\u00ed efektivn\u011bji:<\/h5>\n<ul>\n<li>\n<p><strong>proti retrovir\u016fm, kter\u00e9 nemoc zp\u016fsobuj\u00ed<\/strong>, v ur\u010dit\u00e9 f\u00e1zi nemoci lze dos\u00e1hnout \u00fapln\u00e9 eliminace viru z t\u011bla. Zdrav\u00fd imunitn\u00ed syst\u00e9m disponuje prost\u0159edky, kter\u00e9 mu umo\u017en\u00ed zastavit virus ji\u017e na po\u010d\u00e1tku infekce. Ve f\u00e1zi ji\u017e prob\u00edhaj\u00edc\u00ed nemoci FeLV ji siln\u00e1 imunita dok\u00e1\u017ee zatla\u010dit do regresn\u00ed nebo latentn\u00ed f\u00e1ze. I kdy\u017e je virus ji\u017e zaps\u00e1n do bun\u011bk kostn\u00ed d\u0159en\u011b, m\u016f\u017ee ho soustavn\u00e1 siln\u00e1 imunitn\u00ed odpov\u011b\u010f t\u011bla zcela zni\u010dit. Pr\u00e1v\u011b u chronick\u00fdch infekc\u00ed je nutn\u00e1 sofistikovan\u00e1 specifick\u00e1 stimulace imunity, proto\u017ee d\u00edky dlouhodob\u00e9 snaze zbavit t\u011blo patogenu dojde postupn\u011b k \u00fatlumu n\u011bkter\u00fdch imunitn\u00edch proces\u016f.\u00a0 \u00a0<\/p>\n<\/li>\n<li><strong>proti oportunn\u00edm infek\u010dn\u00edm patogen\u016fm. <\/strong>Ko\u010dky, kter\u00fdm mnoho m\u011bs\u00edc\u016f nebo let ub\u00fdv\u00e1 schopnost se \u00fa\u010dinn\u011b br\u00e1nit d\u00edky jejich oslaben\u00e9 imunit\u011b, um\u00edraj\u00ed \u010dasto na p\u0159idru\u017een\u00e9 nemoci, kter\u00e9 d\u00e1l od\u010derp\u00e1vaj\u00ed energii jejich zdecimovan\u00e9 imunitn\u00ed obran\u011b. Aktivace \u00fa\u010dinn\u00e9 specificky zam\u011b\u0159en\u00e9 imunitn\u00ed odpov\u011bdi pomoc\u00ed TPA zlep\u0161\u00ed schopnost zbavit se oportunn\u00edch infekc\u00ed rychleji a za cenu men\u0161\u00edho n\u00e1sledn\u00e9ho vy\u010derp\u00e1n\u00ed imunity.<\/li>\n<li><strong>na vyhled\u00e1v\u00e1n\u00ed a likvidaci vlastn\u00edch bun\u011bk t\u011bla, kter\u00e9 vykazuj\u00ed<\/strong>\n<ul>\n<li><strong>znaky n\u00e1dorov\u00e9ho zvrhnut\u00ed<\/strong><\/li>\n<\/ul>\n<ul>\n<li><strong>abnormality d\u00edky veps\u00e1n\u00ed virov\u00e9 DNA.<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0TPA je sign\u00e1ln\u00ed molekula, kter\u00e1 se pod\u00edl\u00ed na vyvol\u00e1n\u00ed procesu apopt\u00f3zy infikovan\u00fdch nebo n\u00e1dorov\u00fdch bun\u011bk lymfoidn\u00edho a myeloidn\u00edho p\u016fvodu (provedeny experimenty in vitro i in vivo). Aberantn\u00ed, tedy zm\u011bn\u011bn\u00e9 ne ty zdrav\u00e9, bu\u0148ky po kontaktu s TPA samy spust\u00ed proces sebedestrukce, tedy indukovan\u00e9 \u0159\u00edzen\u00e9 bun\u011b\u010dn\u00e9 smrti bun\u011bk, kter\u00e9 pro t\u011blo p\u0159edstavuj\u00ed nebezpe\u010d\u00ed.<\/p>\n<p>Z\u00e1rove\u0148 d\u016fsledkem stimulace diferenciace CD4+ Th lymfocyt\u016f sm\u011brem k protivirov\u00e9 bun\u011b\u010dn\u00e9 odpov\u011bdi (Th1) se odstartuj\u00ed dal\u0161\u00ed zp\u016fsoby likvidace posti\u017een\u00fdch bun\u011bk a to prost\u0159ednictv\u00edm proces\u016f bun\u011b\u010dn\u00e9 specifick\u00e9 imunitn\u00ed reakce, kter\u00e1 r\u016fzn\u00fdmi zp\u016fsoby vyhled\u00e1 a ni\u010d\u00ed napaden\u00e9 bu\u0148ky.\u00a0<\/p>\n<ul>\n<li><strong>proti anemii a lymfocytopenii, stimuluje hematop\u00e9zu. <\/strong>Aktivovan\u00e9 CD4+ Th lymfocyty sv\u00fdm p\u0159\u00edm\u00fdm p\u016fsoben\u00edm velmi p\u0159esn\u00fdm zp\u016fsobem stimuluj\u00ed kmenov\u00e9 bu\u0148ky kostn\u00ed d\u0159en\u011b. D\u00edky tomu dojde ke zv\u00fd\u0161en\u00ed produkce krevn\u00edch element\u016f, kter\u00e9 jsou pr\u00e1v\u011b v organismu pot\u0159ebn\u00e9. Lymfocytopenie T bun\u011b\u010dn\u00e9 slo\u017eky imunitn\u00ed obrany je kompenzov\u00e1na stimulac\u00ed diferenciace thymocyt\u016f na naivn\u00ed CD4+Th0 lymfocyty a na dal\u0161\u00ed \u00farovni klonov\u00e1n\u00edm aktivovan\u00fdch lymfocyt\u016f v krvi a tk\u00e1n\u00edch s produkc\u00ed cytokin\u016f podporuj\u00edc\u00edch krvetvorbu.\u00a0<\/li>\n<\/ul>\n<figure class=\"wp-block-image\"><img alt=\"\" \/><\/figure>\n<p class=\"has-tertiary-background-color has-background\">\u00a0<\/p>\n\t\t\n<style>\n#text-1747717639 {\n  color: rgb(0,0,0);\n}\n#text-1747717639 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"text-4097487566\" class=\"text\">\n\t\t\n\n<p style=\"text-align: center;\"><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Pokus\u00edme se velmi zjednodu\u0161en\u011b popsat proces, d\u00edky n\u011bmu\u017e TPA ovliv\u0148uje podstatn\u00fdm zp\u016fsobem pr\u016fb\u011bh infekce:<\/span><\/span><\/span><\/p>\n<h1 style=\"text-align: center;\">\u2193<\/h1>\n\t\t\n<style>\n#text-4097487566 {\n  color: rgb(0,0,0);\n}\n#text-4097487566 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-490474331\">\n\n\n\t<div id=\"col-1295930171\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n<div class=\"accordion\">\n\n\t<div id=\"accordion-1037654525\" class=\"accordion-item\">\n\t\t<a id=\"accordion-1037654525-label\" class=\"accordion-title plain\" href=\"#accordion-item-jak\u00e9-procesy-vyvol\u00e1-%20v-t\u011ble-nemocn\u00e9-ko\u010dky-tpa\" aria-expanded=\"false\" aria-controls=\"accordion-1037654525-content\" >\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\"><\/i><\/button>\n\t\t\t<span>Jak\u00e9 procesy vyvol\u00e1  v t\u011ble nemocn\u00e9 ko\u010dky TPA<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-1037654525-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-1037654525-label\" >\n\t\t\t\n\n<ul>\n<li>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">TPA <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">p\u016fsob\u00ed jako d<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">iferencia\u010dn\u00ed sign\u00e1l k <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">zah\u00e1jen\u00ed<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> dozr\u00e1v\u00e1n\u00ed <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">(<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">iniciac<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">e<\/span><\/span><\/span> <span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">maturace)<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> thymocyt\u016f, <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">co\u017e jsou <\/span><\/span><\/span> <span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">prekurzor<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">y<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> CD4+ <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">T <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">lymfocyt\u016f, <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">kter\u00e9 vznikaj\u00ed v kostn\u00ed d\u0159eni<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">. <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">V d\u016fsledku tohoto diferencia\u010dn\u00edho a selek\u010dn\u00edho procesu vznikaj\u00ed funk\u010dn\u00ed naivn\u00ed CD4+ Th lymfocyty (zral\u00e9 \u201eklidov\u00e9\u201c CD4+ Th lymfocyty, kter\u00e9 dosud nepro\u0161ly aktiva\u010dn\u00edm procesem po prezentaci antigenu) a signifikantn\u011b se tak zv\u00fd\u0161\u00ed jejich mno\u017estv\u00ed na periferii<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">. <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Z\u00e1rove\u0148 v dal\u0161\u00edm stupni TPA stimuluje jejich aktivaci a diferenciaci sm\u011brem k Th1 imunitn\u00edmu bun\u011b\u010dn\u00e9mu typu protivirov\u00e9 aktivity. <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> Aktivovan\u00fd lymfocyt okam\u017eit\u011b za\u010dne vys\u00edlat <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">chemick\u00e9 posly nesouc\u00ed instrukce k <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">ostatn\u00edm bu\u0148k\u00e1m, za\u010dne klonovat s\u00e1m sebe a tak zv\u00fd\u0161\u00ed po\u010det \u0159\u00edd\u00edc\u00edch d\u016fstojn\u00edk\u016f imunitn\u00ed arm\u00e1dy. Vys\u00edl\u00e1 velmi speci\u00e1ln\u00ed sign\u00e1ly, kter\u00e9 vedou k c\u00edlen\u00e9mu vyhled\u00e1v\u00e1n\u00ed a likvidaci bun\u011bk napaden\u00fdch virem i virov\u00fdch partikul\u00ed samotn\u00fdch. P\u0159i spr\u00e1vn\u011b nastaven\u00e9 imunitn\u00ed reakci je tento proces komplexn\u00ed a obrana je aktivov\u00e1na z mnoha sm\u011br\u016f. <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">V\u00fdznamn\u00fd efekt pod\u00e1v\u00e1n\u00ed TPA <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">tomto konkr\u00e9tn\u00edm p\u0159\u00edpad\u011b<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> je\u00a0<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">i <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">v tom, \u017ee <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">pozitivn\u011b posiluje <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">pr\u00e1v\u011b tu \u010d\u00e1st imunitn\u00edho syst\u00e9mu, kter\u00fd virus napad\u00e1 a ni\u010d\u00ed.<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Aktivace cytotoxick\u00fdch CD8+ T lymfocyt\u016f p\u016fsoben\u00edm helper\u016f (d\u00edky\u00a0 <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">aktivaci Th1 diferenciace i s p\u0159isp\u011bn\u00edm TPA) <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">vede k likvidaci napaden\u00fdch bun\u011bk i s virem uvnit\u0159. CD8+ lymfocyt napadenou bu\u0148ku doslova rozpust\u00ed, stejn\u011b jako pavouk mouchu. Je tak rychle zastavena produkce nov\u00fdch virov\u00fdch partikul\u00ed. <\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">V \u0159et\u011bzci sign\u00e1l\u016f vyslan\u00fdch aktivovan\u00fdmi <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">CD4+ Th1 <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">lymfocyty se zvy\u0161uje jejich p\u016fsoben\u00edm i mno\u017estv\u00ed <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">a aktivita<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> dal\u0161\u00edch imunitn\u00edch bun\u011bk, jako jsou NK bu\u0148ky (p\u0159irozen\u00ed zabij\u00e1ci), makrof\u00e1gy a dendritick\u00e9 bu\u0148ky, kter\u00e9 se pod\u00edlej\u00ed na boji s infekc\u00ed jin\u00fdm zp\u016fsobem. Z\u00e1rove\u0148 dojde k aktivaci produkce v\u0161ech krevn\u00edch element\u016f <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">a to specificky v z\u00e1vislosti na jejich aktu\u00e1ln\u00ed depleci. Interleukinov\u00e1 signalizace ovliv\u0148uje produkci <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">jak \u010derven\u00fdch <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">a <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">b\u00edl\u00fdch krvinek, tak i krevn\u00edch desti\u010dek. <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Dopln\u011bn\u00ed deficitu n\u011bkter\u00fdch <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">krvinek <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">pak vede k<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> n\u00e1sobn\u011b vy\u0161\u0161\u00ed efektivit<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">\u011b<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> boj<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">e<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> s infekc\u00ed, ale tak\u00e9 <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">k regeneraci po\u0161kozen\u00ed<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">, kter<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">\u00e1<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> nemoc zp\u016fsobila. Stimulace kostn\u00ed d\u0159en\u011b k produkci v\u0161ech typ\u016f krvinek (kterou p\u0159es n\u011bkolik regula\u010dn\u00edch stup\u0148\u016f nep\u0159\u00edmo vyvol\u00e1v\u00e1 TPA) je \u00fa\u010dinn\u00fdm mechanismem kompenzace anemie a pos\u00edlen\u00edm bun\u011b\u010dn\u00e9 imunitn\u00ed reakce na nemoc. <\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p><a name=\"firstHeading\"><\/a><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>T<\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>h1 typ diferenciace<\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> je <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">krom\u011b aktivace a proliferace CD8+ T lymfocyt\u016f <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">rovn\u011b\u017e zodpov\u011bdn\u00fd za produkci interferonu \u03b3, <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">TNF<\/span><\/span><\/span><span style=\"color: #202122;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">-\u03b2<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">, <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">IL-2 a IL-12 <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">a maximalizaci \u00fa\u010dinnosti zab\u00edjen\u00ed u makrof\u00e1g\u016f. Doch\u00e1z\u00ed k podpo\u0159e produkce IgG (opsonizuj\u00edc\u00ed protil\u00e1tky). <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">IFN-\u03b3<\/span><\/span><\/span> <span style=\"color: #202122;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">zvy\u0161uje produkci IL-12 dendritick\u00fdmi bu\u0148kami a makrof\u00e1gy a skrze pozitivn\u00ed zp\u011btnou vazbu, IL-12 stimuluje produkci <\/span><\/span><\/span><span style=\"color: #202122;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">IFN gama <\/span><\/span><\/span><span style=\"color: #202122;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">v Th\u00a0lymfocytech a t\u00edm podporuje diferenciaci v Th1 lymfocyty.<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">\u00a0<\/span><\/span><\/span><a href=\"https:\/\/cs.wikipedia.org\/wiki\/Interferon_%CE%B3\"><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">IFN-y<\/span><\/span><\/span><\/a><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">\u00a0<\/span><\/span><\/span><span style=\"color: #202122;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">tak\u00e9 inhibuje produkci IL-4, \u010d\u00edm\u017e inhibuje vznik Th2 lymfocyt\u016f.<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">C<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">el\u00fd tento proces nen\u00ed chaotick\u00fd, ale podl\u00e9h\u00e1 p\u0159\u00edsn\u00e9 zp\u011btn\u00e9 vazb\u011b, aby nedo\u0161lo k p\u0159ehnan\u00e9 \u0161kodliv\u00e9 autoimunitn\u00ed destrukci. <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Krom\u011b <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>inhibi\u010dn\u00edho p\u016fsoben\u00ed cytokinov\u00e9 signalizace<\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> kontroluje aktivitu Th lymfocyt\u016f<\/span><\/span><\/span> <span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">i Tc lymfocyt\u016f<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b> regula\u010dn\u00ed podskupina Treg lymfocyt\u016f<\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">. TPA jak ji\u017e bylo uvedeno stimuluje maturaci thymocyt\u016f na naivn\u00ed Th0 lymfocyty, kter\u00e9 jsou p\u0159\u00edm\u00fdmi prekurzory Treg lymfocyt\u016f. Touto cestou tedy posiluje zp\u011btnou kontrolu, aby nedo\u0161lo ke \u0161kodliv\u00e9mu vych\u00fdlen\u00ed imunitn\u00ed odpov\u011bdi.<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">CD4+Th lymfocyty maj\u00ed z\u00e1sadn\u00ed roli v procesu, <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">kter\u00fd <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>p\u016fsob\u00ed proti tzv. vy\u010derp\u00e1n\u00ed T bun\u011bk u chronick\u00fdch virov\u00fdch infekc\u00ed, <\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>jak\u00fdmi jsou jak FeLV tak FIV<\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">. Vy\u010derp\u00e1n\u00ed m\u016f\u017ee b\u00fdt spu\u0161t\u011bno celou \u0159adou faktor\u016f jako je nap\u0159\u00edklad p\u0159etrv\u00e1vaj\u00edc\u00ed <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">dlouhodob\u00e9 <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">vystaven\u00ed antigenu (= viru) a ztr\u00e1ta pomoci od <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">CD4+ Th <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">lymfocyt\u016f <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">(nap\u0159\u00edklad i jejich ni\u010den\u00edm virovou infekc\u00ed, k n\u00ed\u017e u obou onemocn\u011bn\u00ed doch\u00e1z\u00ed)<\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">.\u00a0Vystaven\u00ed antigenu m\u00e1 tak\u00e9 efekt na pr\u016fb\u011bh vy\u010derp\u00e1n\u00ed, jeliko\u017e del\u0161\u00ed vystaven\u00ed nebo vy\u0161\u0161\u00ed mno\u017estv\u00ed antigenu m\u00e1 za n\u00e1sledek zhor\u0161en\u00ed vy\u010derp\u00e1n\u00ed. Pro rozvinut\u00ed vy\u010derp\u00e1n\u00ed je t\u0159eba kontinu\u00e1ln\u00ed vystaven\u00ed antigenu po dobu alespo\u0148 2-4 t\u00fddn\u016f. To znamen\u00e1, \u017ee <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>\u010d\u00edm siln\u011bj\u0161\u00ed je <\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>chronick\u00e1 <\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>infekce a \u010d\u00edm d\u00e9le trv\u00e1, t\u00edm v\u00edce paradoxn\u011b sl\u00e1bne reaktivita imunitn\u00edho syst\u00e9mu<\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">. <\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>Stimulace CD4+ <\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>Th<\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b> lymfocyt\u016f <\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>pomoc\u00ed TPA v\u00fd\u0161e zm\u00edn\u011bn\u00fdmi mechanismy m\u016f\u017ee tento stav resetovat a vr\u00e1tit s\u00edlu imunitn\u00ed reakci na infekci<\/b><\/span><\/span><\/span><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">. Proto m\u00e1 ohromn\u00fd v\u00fdznam pod\u00e1v\u00e1n\u00ed TPA i b\u011bhem bezp\u0159\u00edznakov\u00fdch relativn\u011b ne\u0161kodn\u00fdch f\u00e1z\u00ed infekce. <\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Tento mechanismus nen\u00ed v\u00fdmyslem \u010dlov\u011bka, ale funguje v p\u0159\u00edrod\u011b miliony let. TPA nen\u00ed n\u011bjak\u00fd um\u011bl\u00fd chemick\u00fd prost\u0159edek, kter\u00fd m\u016f\u017ee nap\u00e1chat v\u00edce \u0161kody ne\u017e u\u017eitku se spoustou vedlej\u0161\u00edch ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f. P\u0159i pod\u00e1v\u00e1n\u00ed TPA za t\u00e9m\u011b\u0159 t\u0159icet let nebyly zaznamen\u00e1ny \u017e\u00e1dn\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky.<\/span><\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<p><span style=\"color: #0a0a0a;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><span style=\"color: #000000;\">\u00a0 \u00a0 \u00a0 \u010casto je p\u0159i l\u00e9\u010db\u011b FeLV pou\u017e\u00edv\u00e1na terapie interferonem. Biologick\u00e1 \u00fa\u010dinnost TPA se m\u011b\u0159\u00ed jako indukce produkce interferonu gama aktivovan\u00fdmi thymocyty. Terapie pomoc\u00ed rekombinantn\u00edho ko\u010di\u010d\u00edho interferonu je zalo\u017eena na pod\u00e1n\u00ed vysok\u00e9 d\u00e1vky sign\u00e1ln\u00edch molekul (skupiny 1 \u2013 alfa interferon), co\u017e vyvol\u00e1 okam\u017eitou blokaci virov\u00e9 reprodukce v naka\u017een\u00fdch bu\u0148k\u00e1ch. Jedn\u00e1 se o stimulaci nespecifick\u00e9 imunitn\u00ed odpov\u011bdi na infekci. P\u0159esn\u00fd mechanismus nen\u00ed zn\u00e1m, nicm\u00e9n\u011b pro terapii virov\u00fdch imunodeficienc\u00ed je to nesm\u00edrn\u011b efektivn\u00ed zp\u016fsob, jak rychle <\/span><span style=\"color: #000000;\">nespecificky <\/span><span style=\"color: #000000;\">blokovat rozvoj vir\u00e9mie a i kdy\u017e se ko\u010dka nevyl\u00e9\u010d\u00ed, aplikace interferonov\u00e9 k\u016fry v\u00fdrazn\u011b infekci potla\u010d\u00ed. Jistou nev\u00fdhodou je celkem v\u00fdznamn\u00e9 mno\u017estv\u00ed ne\u017e\u00e1douc\u00edch efekt\u016f, asi nejd\u016fle\u017eit\u011bj\u0161\u00ed je deprese kostn\u00ed d\u0159en\u011b.<\/span><\/span><\/span><\/span><\/p>\n<p><span style=\"color: #0a0a0a;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><span style=\"color: #000000;\">\u00a0 \u00a0 \u00a0 Pod\u00e1n\u00ed Thymov\u00e9ho Proteinu A m\u00e1 za n\u00e1sledek aktivaci adaptivn\u00ed \u010d\u00e1sti imunitn\u00edho syst\u00e9mu a t\u00edm p\u00e1dem indukci analogick\u00e9ho procesu p\u0159irozenou cestou p\u0159es \u0159\u00edd\u00edc\u00ed \u00falohu CD4+ T lymfocyt\u016f.\u00a0 Proto m\u00e1 pod\u00e1v\u00e1n\u00ed TPA velk\u00fd v\u00fdznam v pr\u016fb\u011bhu cel\u00e9ho \u017eivota imunosuprimovan\u00fdch ko\u010dek. P\u0159irozen\u00e1 produkce interferon\u016f nen\u00ed tak masivn\u00ed a jednor\u00e1zov\u00e1, ale je specifick\u00e1, p\u0159esn\u00e1 a trv\u00e1 do t\u00e9 doby, dokud je indukovan\u00e1 p\u0159\u00edtomnost\u00ed viru. Je u\u017eite\u010dn\u00e9 samoz\u0159ejm\u011b vyu\u017e\u00edt v\u0161echny mo\u017enosti l\u00e9\u010dby a TPA je p\u0159irozenou mo\u017enost\u00ed, jak mobilizovat imunitn\u00ed syst\u00e9m mj. i k p\u0159irozen\u00e9 produkci interferon\u016f a dal\u0161\u00edch sign\u00e1ln\u00edch molekul b\u011bhem cel\u00e9ho \u017eivota nemocn\u00fdch zv\u00ed\u0159at a trvale tak napom\u00e1hat v boji s virem a to bez ne\u017e\u00e1douc\u00edch vedlej\u0161\u00edch \u00fa\u010dink\u016f. T\u011blo samo vyr\u00e1b\u00ed v\u0161echny pot\u0159ebn\u00e9 sign\u00e1ln\u00ed molekul\u00e1rn\u00ed posly pot\u0159ebn\u00e9 k \u0159\u00edzen\u00ed adekv\u00e1tn\u00ed imunitn\u00ed reakce na infekci, v\u010detn\u011b interferon\u016f alfa. Hlavn\u00edm producentem tohoto typu interferonu jsou makrof\u00e1gy, p\u0159edstavitel\u00e9 nespecifick\u00e9 imunity <\/span><span style=\"color: #000000;\">ale tak\u00e9 efektorov\u00fdmi bu\u0148kami Th1 typu imunitn\u00ed odpov\u011bdi<\/span><span style=\"color: #000000;\">. Jejich <\/span><span style=\"color: #000000;\">produkce<\/span><span style=\"color: #000000;\"> je ovlivn\u011bn<\/span><span style=\"color: #000000;\">\u00e1<\/span><span style=\"color: #000000;\"> mj. stimulac\u00ed kmenov\u00fdch bun\u011bk interleukiny produkovan\u00fdmi aktivovan\u00fdmi CD4+ lymfocyty.\u00a0\u00a0Interferony a cytokiny jsou pr\u00e1v\u011b t\u011bmi posly, pomoc\u00ed nich\u017e vys\u00edl\u00e1 aktivovan\u00fd CD4+ Th lymfocyt sv\u00e9 p\u0159\u00edkazy a v \u0159et\u011bzci aktiva\u010dn\u00edch sign\u00e1l\u016f tvo\u0159\u00ed dal\u0161\u00ed imunitn\u00ed bu\u0148ky celou plej\u00e1du jin\u00fdch informa\u010dn\u00edch molekul se zcela konkr\u00e9tn\u00edmi \u00fakoly.<\/span><\/span><\/span><\/span><\/p>\n<p>\u00a0<\/p>\n\n\t\t<\/div>\n\t<\/div>\n\t\n\n<\/div>\n\t<div id=\"gap-618033524\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-618033524 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-490474331 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Ze zp\u011btn\u00e9 vazby, kterou jsme z\u00edskali od majitel\u016f nemocn\u00fdch ko\u010di\u010dek plyne, \u017ee profit je hodn\u011b z\u00e1visl\u00fd na st\u00e1diu nemoci, ve kter\u00e9m se pacient nach\u00e1z\u00ed a hlavn\u011b v mno\u017estv\u00ed jin\u00fdch nemoc\u00ed, se kter\u00fdmi ko\u010dka bojuje. Pokud se ale zas\u00e1hne v\u010das, soub\u011b\u017en\u00e9 druhotn\u00e9 zdravotn\u00ed komplikace se poda\u0159\u00ed l\u00e9\u010debn\u011b zvl\u00e1dnout nasazen\u00edm vhodn\u00e9 terapie pod veden\u00edm veterin\u00e1\u0159e, mohou se i relativn\u011b hodn\u011b nemocn\u00e1 zv\u00ed\u0159ata stabilizovat a vr\u00e1tit k norm\u00e1ln\u00edmu plnohodnotn\u00e9mu \u017eivotu v remisi bez p\u0159\u00edznak\u016f nemoci. TPA je u ko\u010dek v zahrani\u010d\u00ed b\u011b\u017en\u011b \u00fasp\u011b\u0161n\u011b u\u017e\u00edvan\u00fd ji\u017e od roku 2008 a pokud se nepoda\u0159\u00ed pacienta uv\u00e9st do \u00fapln\u00e9 remise, alespo\u0148 v\u00fdrazn\u011b pom\u00e1h\u00e1 se zvl\u00e1d\u00e1n\u00edm oportunn\u00edch infekc\u00ed a zlep\u0161en\u00edm komfortu \u017eivota nemocn\u00fdch ko\u010dek. Samoz\u0159ejm\u011b alfa a omega dobr\u00e9 progn\u00f3zy je kvalitn\u00ed symptomatick\u00e1 l\u00e9\u010dba v\u0161ech zdravotn\u00edch komplikac\u00ed pod veden\u00edm veterin\u00e1\u0159e. ProBoost nen\u00ed samospasiteln\u00fdm z\u00e1zra\u010dn\u00fdm medikamentem, ale t\u011blo samo s jeho podporou mus\u00ed sv\u016fj boj dot\u00e1hnout do v\u00edt\u011bzn\u00e9ho konce. Jak\u00e1koliv dal\u0161\u00ed odborn\u00e1 pomoc je tak naprosto nezbytn\u00fdm atributem pro \u00fasp\u011b\u0161n\u00fd postup proti nemoci\u00a0<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Nejlep\u0161\u00ed efekt je mo\u017en\u00e9 o\u010dek\u00e1vat u ko\u010dek bu\u010f v prvn\u00edm st\u00e1diu infekce nebo v p\u0159\u00edpad\u011b regresn\u00ed \u010di latentn\u00ed f\u00e1ze druh\u00e9ho st\u00e1dia nemoci.<\/span><\/span><\/span><strong><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">\u00a0<\/span><\/span><\/span><\/strong><strong><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"><b>Za t\u011bchto podm\u00ednek lze uva\u017eovat i o \u00fapln\u00e9m vyl\u00e9\u010den\u00ed z nemoci vlastn\u00ed silnou imunitn\u00ed reakc\u00ed t\u011bla pos\u00edlenou pod\u00e1v\u00e1n\u00edm ProBoostu.<\/b><\/span><\/span><\/span><\/strong><\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<div class=\"row\"  id=\"row-2441632\">\n\n\n\t<div id=\"col-1635845280\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-2067084193\" class=\"text\">\n\t\t\n\n<h3 style=\"text-align: center;\">D\u00e1vkov\u00e1n\u00ed<\/h3>\n<p><strong>Je nutn\u00e9 \u00fazce spolupracovat s veterin\u00e1\u0159em a po cel\u00fd \u017eivot ko\u010di\u010d\u00edho pacienta v\u011bnovat zv\u00fd\u0161enou pozornost jeho aktu\u00e1ln\u00edmu zdravotn\u00edmu stavu. Je zcela z\u00e1sadn\u00ed ve\u0161ker\u00e9 zdravotn\u00ed komplikace v prvn\u00ed \u0159ad\u011b \u0159e\u0161it dostupnou symptomatickou l\u00e9\u010dbou pod dohledem veterin\u00e1\u0159e. Pokud m\u00e1 jak\u00e1koliv l\u00e9\u010dba v\u00e9st k \u00fasp\u011bchu, mus\u00ed b\u00fdt komplexn\u00ed a vyu\u017e\u00edt v\u0161echny mo\u017enosti, kter\u00e9 m\u00e1 modern\u00ed veterin\u00e1rn\u00ed medic\u00edna k dispozici. ProBoost nen\u00ed univerz\u00e1ln\u00ed z\u00e1zra\u010dn\u00fd lektvar na v\u0161echny neduhy a i kdy\u017e je nesm\u00edrn\u011b \u00fa\u010dinn\u00fd,\u00a0 je t\u0159eba postupovat racion\u00e1ln\u011b a pokud ko\u010di\u010dka pot\u0159ebuje \u0159e\u0161it z\u00e1va\u017en\u00fd zdravotn\u00ed probl\u00e9m, je nutn\u00e9 j\u00ed poskytnout v\u0161echnu dostupnou l\u00e9\u010dbu. U tak z\u00e1va\u017en\u00e9 diagn\u00f3zy, jakou je FeLV nen\u00ed prostor na neuv\u00e1\u017een\u00e9 experimenty. ProBoost p\u016fsob\u00ed na p\u0159\u00ed\u010dinu nemoci, jej\u00ed fyzick\u00e9 n\u00e1sledky m\u016f\u017ee mnohdy pozitivn\u011b ovlivnit tak\u00e9 a urychlit uzdraven\u00ed, ale bylo by nap\u0159\u00edklad v p\u0159\u00edpad\u011b bakteri\u00e1ln\u00ed komplikace krajn\u011b nezodpov\u011bdn\u00e9 nepou\u017e\u00edt antibiotika a podobn\u011b&#8230; V p\u0159\u00edpad\u011b v\u00e1\u017en\u00fdch zdravotn\u00edch pot\u00ed\u017e\u00ed je nutn\u00e9 pacienta stabilizovat v\u0161emi dostupn\u00fdmi prost\u0159edky. Dal\u0161\u00ed imunostimulanty nebo imunomodul\u00e1tory je v\u0161ak t\u0159eba pou\u017e\u00edvat s rozvahou a s ohledem na zp\u016fsob, jak\u00fdm zasahuj\u00ed do imunitn\u00edch proces\u016f a jak\u00fdm zp\u016fsobem mohou ovlivnit aktu\u00e1ln\u00ed zdravotn\u00ed stav. Nen\u00ed nap\u0159\u00edklad rozumn\u00e9 stimulovat nespecificky imunitu, kdy\u017e m\u00e1 ko\u010di\u010dka vysok\u00fd titr protil\u00e1tek proti FeCoV, nebo neuv\u00e1\u017een\u00fdm v\u00fdb\u011brem imunostimulantu prohloubit chybnou autoimunitn\u00ed\u00a0 reakci.<\/strong><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">P\u016fvodn\u00ed studie uv\u00e1d\u011bla mnohaletou bezp\u0159\u00edznakovou remisi po t\u0159ech inicia\u010dn\u00edch injek\u010dn\u00edch d\u00e1vk\u00e1ch a pot\u00e9 m\u011bl b\u00fdt LTCI individu\u00e1ln\u011b aplikov\u00e1n jednou za jeden a\u017e dva m\u011bs\u00edce, v praxi byly mnohdy nutn\u00e9 aplikace i v krat\u0161\u00edm intervalu, nap\u0159\u00edklad v t\u011b\u017ek\u00fdch p\u0159\u00edpadech jednou t\u00fddn\u011b, v\u017edy tedy individu\u00e1ln\u011b podle stavu pacienta.\u00a0<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">D\u00e1vkov\u00e1n\u00ed ProBoostu, doporu\u010duj\u00ed veterin\u00e1\u0159i pro dosp\u011blou ko\u010dku p\u016fl s\u00e1\u010dku na den, l\u00e9pe ve dvou d\u00e1vk\u00e1ch po 12 hodin\u00e1ch a po \u010dtvrtin\u011b s\u00e1\u010dku. N\u00e1stup \u00fa\u010dinku trv\u00e1 trochu d\u00e9le, ne\u017e p\u0159i injek\u010dn\u00ed aplikaci LTCI. Sta\u010d\u00ed v\u0161ak TPA po men\u0161\u00edch d\u00e1vk\u00e1ch pr\u016fb\u011b\u017en\u011b dopl\u0148ovat k zaji\u0161t\u011bn\u00ed dostate\u010dn\u00e9 koncentrace pro pot\u0159eby stimulace maturace a n\u00e1sledn\u00e9 aktivace zral\u00fdch lymfocyt\u016f a vyvol\u00e1n\u00ed apopt\u00f3zy naka\u017een\u00fdch bun\u011bk. Jakmile je zv\u00ed\u0159e po n\u011bkolika t\u00fddnech stabilizovan\u00e9, sta\u010d\u00ed udr\u017eovac\u00ed d\u00e1vka, kter\u00e1 z\u00e1vis\u00ed na posouzen\u00ed zdravotn\u00edho stavu konkr\u00e9tn\u00ed ko\u010di\u010dky, zejm\u00e9na vyhodnocen\u00ed krevn\u00edho obrazu \u2013 hladina b\u00edl\u00fdch krvinek\u2026. Doporu\u010dujeme d\u00e1le pokra\u010dovat alespo\u0148 v minim\u00e1ln\u00ed udr\u017eovac\u00ed d\u00e1vce, kter\u00e1 z\u00e1vis\u00ed na posouzen\u00ed individu\u00e1ln\u00edho zdravotn\u00edho stavu a m\u016f\u017ee b\u00fdt nap\u0159\u00edklad \u010dtvrt s\u00e1\u010dku na den nebo jednou a\u017e dvakr\u00e1t t\u00fddn\u011b. I zcela zdrav\u00e9mu jedinci je pod\u00e1v\u00e1n\u00ed TPA ka\u017ed\u00fd den pro pos\u00edlen\u00ed imunity prosp\u011b\u0161n\u00e9, nehroz\u00ed p\u0159ed\u00e1vkov\u00e1n\u00ed, tak\u017ee po prod\u011bl\u00e1n\u00ed tak z\u00e1va\u017en\u00e9 infekce, jakou je FeLV nebo FIV je ur\u010dit\u011b na m\u00edst\u011b pokra\u010dovat v pod\u00e1v\u00e1n\u00ed TPA ve frekvenci, kter\u00e1 je v podstat\u011b na rozhodnut\u00ed majitele ide\u00e1ln\u011b po konzultaci s veterin\u00e1\u0159em, kter\u00fd vyhodnot\u00ed kondici pacienta. V pr\u016fb\u011bhu \u017eivota se m\u016f\u017ee s d\u00e1vkou pracovat podle konkr\u00e9tn\u00ed situace. Pokud se v\u00fdsledky zhor\u0161\u00ed, nasad\u00ed se vy\u0161\u0161\u00ed d\u00e1vka, pokud budou v\u00fdsledky excelentn\u00ed, m\u016f\u017ee se podpora imunity pacienta sn\u00ed\u017eit na minimum. Pokud b\u011b\u017e\u00ed sou\u010dasn\u011b n\u011bjak\u00e1 v\u00e1\u017en\u00e1 autoimunita, m\u016f\u017ee b\u00fdt d\u00e1vkov\u00e1n\u00ed klidn\u011b jeden nebo dva s\u00e1\u010dky na den. Ka\u017ed\u00fd majitel mus\u00ed sledov\u00e1n\u00edm odpov\u011bdi na imunostimulaci \u201cvytitrovat\u201d optim\u00e1ln\u00ed d\u00e1vkov\u00e1n\u00ed pro vymizen\u00ed pot\u00ed\u017e\u00ed.<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">V prvn\u00edm st\u00e1diu infekce nebo v p\u0159\u00edpad\u011b regresn\u00ed \u010di latentn\u00ed f\u00e1ze druh\u00e9ho st\u00e1dia nemoci doporu\u010dujeme pod\u00e1vat l\u00e9pe p\u016fl nejm\u00e9n\u011b \u010dtvrt s\u00e1\u010dku na den a pr\u016fb\u011b\u017en\u011b po n\u011bkolika t\u00fddnech nebo m\u011bs\u00edc\u00edch po konzultaci s veterin\u00e1\u0159em prov\u00e9st laboratorn\u00ed ov\u011b\u0159en\u00ed pr\u016fb\u011bhu infekce v nad\u011bji, \u017ee se nad nemoc\u00ed poda\u0159\u00ed zv\u00edt\u011bzit. Tento proces m\u016f\u017ee trvat t\u00fddny nebo i m\u011bs\u00edce \u010di roky. Je t\u0159eba se ozbrojit trp\u011blivost\u00ed a vytrvat v nad\u011bji, \u017ee siln\u00e1 imunita podpo\u0159en\u00e1 ProBoostem p\u0159esn\u011b na spr\u00e1vn\u00e9m m\u00edst\u011b sama dok\u00e1\u017ee nad nemoc\u00ed zv\u00edt\u011bzit. Vy\u0161\u0161\u00ed pravideln\u00e9 pod\u00e1v\u00e1n\u00ed ProBoostu je mo\u017en\u00e9 tak\u00e9 pokud se chceme pokusit zbrzdit a potla\u010dit perzistentn\u00ed viremii.<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Samoz\u0159ejm\u011b je nasnad\u011b u\u017eite\u010dn\u00e1 mo\u017enost krom\u011b pod\u00e1v\u00e1n\u00ed ProBoostu i dopln\u011bn\u00ed l\u00e9\u010dby o dal\u0161\u00ed l\u00e9\u010debn\u00e9 a nutri\u010dn\u00ed p\u0159\u00edpravky a dal\u0161\u00ed produkty na podporu imunity, jako jsou betaglukany atp.<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">V r\u00e1mci l\u00e9\u010dby imunodeficientn\u00edch pacient\u016f FeLV, FIV, po terapii FIP jsou \u010dasto pou\u017e\u00edv\u00e1ny podp\u016frn\u00e9 prost\u0159edky bez l\u00e9ka\u0159sk\u00e9ho p\u0159edpisu. D\u016frazn\u011b varujeme a\u00a0 v\u017edy u tak v\u00e1\u017en\u00e9 nemoci doporu\u010dujeme konzultaci s odborn\u00edkem. Jak u\u017e poznali pejsek s ko\u010di\u010dkou, kdy\u017e pekli dort, i v\u0161eho dobr\u00e9ho m\u016f\u017ee b\u00fdt p\u0159\u00edli\u0161.<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\"> Imunoglukany, co\u017e je komplex polysacharid\u016f s \u00fa\u010dinkem na nespecifick\u00e9 imunitn\u00ed procesy, lze samoz\u0159ejm\u011b doporu\u010dit. Pokud zvol\u00edte variantu sirupu s p\u0159id\u00e1van\u00fdm vitam\u00ednem C, je t\u0159eba jist\u00e9 opatrnosti. Chronick\u00e1 aplikace vitam\u00ednu C ve vysok\u00e9 d\u00e1vce m\u016f\u017ee v\u00fdznamn\u011b okyselit mo\u010d a vzniknou tak probl\u00e9my s oxal\u00e1ty. V p\u0159im\u011b\u0159en\u00e9m mno\u017estv\u00ed lze vitamin C samoz\u0159ejm\u011b i dlouhodob\u011b jednozna\u010dn\u011b doporu\u010dit. Dlouhodob\u00e1 trval\u00e1 stimulace nespecifick\u00e9 imunity p\u0159edkl\u00e1d\u00e1n\u00edm t\u011bchto imunogenn\u00edch biologicky aktivn\u00edch polysacharid\u016f m\u016f\u017ee \u010dasem v\u00e9st k vy\u010derp\u00e1n\u00ed a poklesu v\u00fdsledn\u00e9ho efektu, proto p\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed je l\u00e9pe alespo\u0148 kr\u00e1tkodob\u011b pod\u00e1v\u00e1n\u00ed vynech\u00e1vat.\u00a0\u00a0<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Hojn\u011b jsou v dobr\u00e9 v\u00ed\u0159e pou\u017e\u00edv\u00e1ny a doporu\u010dov\u00e1ny r\u016fzn\u00e9 produkty z bylinek atp.\u00a0 Hlavn\u011b u chronick\u00fdch pacient\u016f p\u0159ed dlouhodob\u00fdm pod\u00e1v\u00e1n\u00edm se v\u0161\u00ed d\u016fraznost\u00ed varujeme! Je t\u0159eba si uv\u011bdomit, \u017ee v\u00fdta\u017eky z rostlin jsou vlastn\u011b l\u00e9ky p\u0159\u00edrodn\u00edho p\u016fvodu a jako takov\u00e9 se mus\u00ed pou\u017e\u00edvat s rozvahou a v\u017edy po konzultaci s odborn\u00edky. Kr\u00e1tkodob\u011b a v p\u0159im\u011b\u0159en\u00e9m mno\u017estv\u00ed jsou nesm\u00edrn\u011b u\u017eite\u010dn\u00e9, v\u017edy ale s ohledem na znalost vedlej\u0161\u00edch rizik a ne\u017e\u00e1douc\u00edho p\u016fsoben\u00ed.\u00a0<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">N\u011bkolik p\u0159\u00edklad\u016f rostlin, kter\u00e9 jsou sou\u010d\u00e1st\u00ed bylinn\u00fdch prepar\u00e1t\u016f doporu\u010dovan\u00fdch u ko\u010di\u010dek s FIV a FeLV na pos\u00edlen\u00ed imunity:<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Aloe vera je klenot mezi l\u00e9\u010div\u00fdmi rostlinami. Je dob\u0159e si ale zjistit, zda v\u00fdrobek m\u00e1 certifik\u00e1t o p\u016fvodu (IASC). Rozd\u00edl mezi aloe, kter\u00e9 vyrostlo na speci\u00e1ln\u00ed p\u016fd\u011b ve specifick\u00fdch p\u0159\u00edrodn\u00edch podm\u00ednk\u00e1ch a kdekoli jinde m\u016f\u017ee b\u00fdt takov\u00fd, jako mezi marihuanou a technick\u00fdm konop\u00edm. Krom\u011b toho, \u017ee ur\u010dit\u00e9 \u010d\u00e1sti listu jsou toxick\u00e9 a siln\u011b proj\u00edmav\u00e9, nen\u00ed vhodn\u00e9 pou\u017eit\u00ed u pacient\u016f s cukrovkou, p\u0159ed operacemi \u2013 vy\u0161\u0161\u00ed krv\u00e1civost, u srde\u010dn\u00edch onemocn\u011bn\u00ed tak\u00e9 pozor \u2013 zvy\u0161uje tepovou frekvenci, co\u017e m\u016f\u017ee kardiaka zab\u00edt. U onemocn\u011bn\u00ed HCM, kter\u00e9 se u ko\u010dek vyskytuje celkem \u010dasto nebo p\u0159i myopatii zp\u016fsoben\u00e9 virovou infekc\u00ed (nap\u0159\u00edklad FIP) m\u016f\u017ee vyvolat fat\u00e1ln\u00ed komplikace. D\u00e1le je ve h\u0159e probl\u00e9m se \u017elu\u010dn\u00edkem, po\u0161kozen\u00edm \u017ealudku a u ko\u010dek obecn\u011b velmi citliv\u00fdch na po\u0161kozen\u00ed ledvin m\u016f\u017ee b\u00fdt p\u0159\u00ed\u010dinou jejich selh\u00e1n\u00ed.<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Kukurma, resp. kukurmin v n\u00ed obsa\u017een\u00fd je nesm\u00edrn\u011b prosp\u011b\u0161n\u00fd a \u00fa\u010dinky na imunitu zejm\u00e9na u FeLV a FIV infekc\u00ed jsou v\u011bdecky potvrzen\u00e9. I tady v\u0161ak pozor. Krom\u011b toho, \u017ee m\u016f\u017ee vyvolat alergii, m\u016f\u017ee p\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed zp\u016fsobit za\u017e\u00edvac\u00ed pot\u00ed\u017ee, zvracen\u00ed, intoxikaci jater a pr\u016fjem. Vy\u0161\u0161\u00ed d\u00e1vka m\u016f\u017ee st\u00e1t za vznikem v\u0159ed\u016f.<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">T\u0159ezalka te\u010dkovan\u00e1 by nem\u011bla b\u00fdt pod\u00e1v\u00e1na ko\u010dk\u00e1m, na kter\u00e9 m\u016f\u017ee dopadnout slune\u010dn\u00ed z\u00e1\u0159en\u00ed, nesm\u00ed ven, ani do voli\u00e9ry nebo k oknu bez zatemn\u011bn\u00ed. Zp\u016fsobuje toti\u017e p\u0159ecitliv\u011blost poko\u017eky a v\u00e1\u017en\u00e9 sp\u00e1leniny hlavn\u011b na m\u00e9n\u011b osrst\u011bn\u00fdch \u010d\u00e1stech t\u011bla. U plemen jako je sphynx atp. je z tohoto d\u016fvodu kontraindikov\u00e1na. Krom\u011b toho op\u011bt p\u0159i del\u0161\u00edm u\u017e\u00edv\u00e1n\u00ed hroz\u00ed \u0161ed\u00fd z\u00e1kal, vysok\u00fd cholesterol, po\u0161kozen\u00ed jater, poruchy sp\u00e1nku, nedoporu\u010duje se diabetik\u016fm a velice rizikov\u00e9 je u\u017eit\u00ed u kardiak\u016f. I zdrav\u00fdm ko\u010dk\u00e1m m\u016f\u017ee vyvolat poruchy srde\u010dn\u00edho rytmu..<\/span><\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"font-family: Liberation Serif, serif;\"><span style=\"font-size: medium;\">Pokud budou produkty tohoto typu na vlasn\u00ed nebezpe\u010d\u00ed u\u017e\u00edv\u00e1ny s v\u011bdom\u00edm v\u0161ech rizik soub\u011b\u017en\u011b s ProBoostem, nelze jejich ne\u017e\u00e1douc\u00ed p\u016fsoben\u00ed p\u0159i\u010d\u00edtat TPA, ale pouze t\u011bmto produkt\u016fm. Soub\u011b\u017en\u00e9 pou\u017e\u00edv\u00e1n\u00ed lze doporu\u010dit pouze kr\u00e1tkodob\u011b nap\u0159\u00edklad b\u011bhem stabiliza\u010dn\u00ed f\u00e1ze nebo samoz\u0159ejm\u011b opakovan\u011b formou ozdravn\u00e9 k\u016fry a se z\u0159etelem na jejich vliv na dal\u0161\u00ed onemocn\u011bn\u00ed pacienta (cukrovka, nemoci srdce, jater, ledvin\u2026). Jedin\u011b tak mohou b\u00fdt opravdovou a \u00fa\u010dinnou pomoc\u00ed pro nemocn\u00e1 zv\u00ed\u0159ata a p\u0159edat jim z p\u0159\u00edrody sv\u00fdm prost\u0159ednictv\u00edm jen to pozitivn\u00ed.\u00a0<\/span><\/span><\/span><\/p>\n<p>\u00a0<\/p>\n\t\t\n<style>\n#text-2067084193 {\n  color: rgb(0,0,0);\n}\n#text-2067084193 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\t<div id=\"text-1621042570\" class=\"text\">\n\t\t\n\n\n\t\t\n<style>\n#text-1621042570 {\n  color: rgb(0,0,0);\n}\n#text-1621042570 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-1535051778\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1535051778 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n<div class=\"row\"  id=\"row-1648599706\">\n\n\n\t<div id=\"col-1602347359\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n<div class=\"row\"  id=\"row-1981102057\">\n\n\n\t<div id=\"col-759819351\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-4061987850\" class=\"text\">\n\t\t\n\n<p>\u00a0V\u00fdsledky experiment\u016f, kter\u00e9 potvrzuj\u00ed \u00falohu brzl\u00edkov\u00e9ho proteinu A v organismu jsou uvedeny v kapitole\u00a0 s n\u00e1zvem <a href=\"\/en_us\/clanky\/\">Publications<\/a>. Informace o \u00faloze CD4+ Th lymfocytu v imunitn\u00edm syst\u00e9mu v \u010dl\u00e1nku <a href=\"\/en_us\/cd4-th-lymfocyt\/\">Thymic Protein A aktivuje naivn\u00ed CD4+Th Lymfocyty.<\/a> Vliv TPA na bun\u011b\u010dnou apopt\u00f3zu v \u010dl\u00e1nku: <a href=\"\/en_us\/apoptoza\/\">Thymic Protein A stimuluje apopt\u00f3zu malign\u00edch a infikovan\u00fdch bun\u011bk<\/a>. Ovlivn\u011bn\u00ed hematopo\u00e9zy popisuje \u010dl\u00e1nek <a href=\"\/en_us\/thymic-protein-a-stimuluje-hematopoezu\/\">Thymic protein A stimuluje hematopo\u00e9zu v\u0161ech krevn\u00edch element\u016f<\/a>. V\u00fdsledky n\u011bkter\u00fdch experiment\u016f a review shrnuj\u00edc\u00ed z\u00edskan\u00e9 poznatky vlivu TPA\/LCTI na imunodeficientn\u00ed ko\u010dky naleznete v odkazu n\u00ed\u017ee.<\/p>\n<h1 style=\"text-align: center;\"><strong>\u2193<\/strong><\/h1>\n\t\t\n<style>\n#text-4061987850 {\n  color: rgb(0,0,0);\n}\n#text-4061987850 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-1349382257\">\n\n\n\t<div id=\"col-405892248\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-750339723\" class=\"text\">\n\t\t\n\n<p style=\"text-align: center;\"><a href=\"http:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Document-1-1.pdf\">Document<\/a><\/p>\n\t\t\n<style>\n#text-750339723 {\n  text-align: center;\n}\n<\/style>\n\t<\/div>\n\t\n<a href=\"https:\/\/patents.google.com\/patent\/US5616554A\/en\" class=\"button primary is-outline box-shadow-5 box-shadow-5-hover expand\"  style=\"border-radius:10px;\">\n\t\t<span>EXAMPLE IV Clinical Protocol, Example V a VI<\/span>\n\t<\/a>\n\n\n<a href=\"http:\/\/tcyte.com\/downloads\/ltci-review.pdf\" class=\"button primary is-outline box-shadow-5 box-shadow-5-hover expand\"  style=\"border-radius:10px;\">\n\t\t<span>Lymphocyte T-Cell Immunomodulator (LTCI): Review of the Immunopharmacology of a New Veterinary Biologic<\/span>\n\t<\/a>\n\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-1349382257 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n<div class=\"row\"  id=\"row-1990913973\">\n\n\n\t<div id=\"col-1152867277\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"gap-1931565917\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1931565917 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div id=\"gap-1718100995\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1718100995 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1779","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages\/1779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/comments?post=1779"}],"version-history":[{"count":0,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages\/1779\/revisions"}],"wp:attachment":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/media?parent=1779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}